Pfizer VPS has launched a 'Pre-Sale Scab Treatment Certificate' so that sheep treated for sheep scab and protected against re-infestation beyond their autumn sale date can be formally certified as such.
A choice of two moxidectin-based treatments are eligible for use, one with 28 days and the other 60 days licensed persistency against the scab mite.
Pfizer VPS vet David Bartram explained that following treatment, the sale date must fall within the persistency window: "The idea is that farmers present their certificate at markets on sale day, then auctioneers announce the scab-protected status during their sales patter. Whether this adds to the sale price will be interesting to find out, but it's sure to be seen as a valuable attribute by buyers who won't need to treat for scab when they arrive home."
Details of the certification process are available from SQPs at animal medicine suppliers. The two eligible treatments are CYDECTIN 1% LA and CYDECTIN 2% LA for sheep.
The EU Commission has approved the marketing authorisation variation of Boehringer Ingelheim's PCV2 vaccine Ingelvac CircoFLEX. This approval allows the combined use of the pig vaccines Ingelvac CircoFLEX and Ingelvac MycoFLEX in the European Union.
Boehringer says it will market this unique vaccine concept under the name FLEXcombo. The company highlights that protection against two of the most prominent and costly pig diseases, Porcine Circovirus Disease (PCVD) and Enzootic Pneumonia, can now be achieved with a single injection instead of up to four injections. More than 70% of European pigs are currently vaccinated against both these diseases.
According to the company, the combined use of Ingelvac CircoFLEX and Ingelvac MycoFLEX is already registered and widely used in North America and Asia. It is globally the first and only product combination of its kind.
Dr. Joachim Hasenmaier, global head of Animal Health within BI said: "We are very proud that we can now also supply EU veterinarians and farmers with this latest innovation that will help tremendously in reducing the number of injections to pigs, supporting the wellbeing of the animals and the farm economics by saving a substantial amount of labour."
Vetoquinol is advising vets and farmers to be on the lookout following the discovery of counterfeit Marbocyl on two farms in Northern Ireland.
The counterfeit product contains an unapproved source of Marbofloxacin in an untested formulation which presents an unknown risk to animal and human health if used.
Vetoquinol has informed the national authorities about this situation. It is illegal either to sell or supply the product or to knowingly buy and/or use it.
The withdrawal period of this counterfeit product is unknown. Should the product be used it could be detected in milk or after slaughter. Vetoquinol advises the veterinary community to be aware of the risk, to carefully check the product packaging before use and to continue to source the product from reputable suppliers.
Vetoquinol urges vets and farmers to take the following actions if you find this product on farm or are approached to purchase it:
Vetoquinol says vets can rest assured that it will do all that is necessary to remove this product from the market.
If you need further information or advice, do not hesitate to contact Vetoquinol on 0800 1698197.
The industry-led Cattle Health and Welfare Group of Great Britain (CHAWG) has published a review which identifies a practical approach to gathering antibiotic usage data on UK cattle farms.
The review outcomes, announced today at a joint conference held by the Responsible Use of Medicines in Agriculture Alliance (RUMA) and the Veterinary Medicines Directorate (VMD), highlight the significant benefits better data could deliver, such as improving the way antibiotics are administered strategically to tackle disease.
But CHAWG’s chair Tim Brigstocke says it’s also important that the industry is able to accurately report usage levels because of the rising levels of antibiotic-resistant bacteria which threaten human health.
"We found that while data is already stored at every vet practice and in every farm medicine book, it currently exists in many different forms. It’s also not collected or collated, and is further complicated by multi-species approvals for many of the antibiotics.
"This means we can’t always be sure in which type of animal a medicine has been used. For example, out of 420 tonnes of animal-authorised antibiotic active substance sold in the UK in 2013, only 14 tonnes was authorised solely for use in cattle. However, 63 tonnes was authorised for multi-species use in food producing animals and within the 217 products included in this, 201 are authorised for use in cattle."
Tim says that with the support of the VMD, which requested the review and will now act as secretariat, CHAWG will set up a working group to implement the report’s recommendations.
The starting point is likely to be the survey of vets carried out by the British Cattle Veterinary Association (BCVA), which formed part of the review. This suggested vets could be using as many as 15 different software programmes to log data, so CHAWG will be working with the BCVA and individual practices to look at how standard sets of data can be anonymised and exported.
"Then we will almost certainly look at how cattle farmers can be supported in migrating records from the physical ‘medicine book’ on the farm, into a spreadsheet or existing cattle management software for anonymous aggregation on a national level.
"There are undoubtedly areas where we can improve the effectiveness of how we use these powerful medicines to improve welfare. But the antibiotic resistance debate is an emotive one and we must also demonstrate accountability to ensure the preservation of antibiotics for future use in humans and animals; any future curbs on usage should be proportionate and informed, and not compromise animal wellbeing."
Mandatory reporting in Europe could be just over the horizon and the European Medicines Agency has focused in the past year on developing a method for data collection on the usage of antibiotics in the EU pig sector. In the UK, the VMD is encouraging the livestock sectors to develop systems appropriate to their own unique circumstances and industry characteristics.
Tim said: "It’s therefore in cattle farmers’ own interests to anticipate the kind of figures it might be asked to supply in the future, and develop a way of collecting that data which suits the way the UK industry works.
"Then we can retain control over the data and the methodology, and ensure the reporting is accurate – and this in turn will help the VMD represent our case better in Europe as this debate continues.
CHAWG says that throughout this project, it will be liaising with others – such as the pig sector – to ensure learnings are shared, duplication avoided and efficiencies realised where possible.
The CHAWG review report is available to download at www.chawg.org.uk.
Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.
The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.
Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.
Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.
Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.
Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.
Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.
Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."
Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.
References
The divestment is expected to be concluded in mid-2020, and Bayer intends to exit its stake in Elanco over time.
Bayer says that combining Elanco and Bayer Animal Health will create the number two animal heath company, with top three positions across a broad range of species and geographies. It also enhances Elanco’s portfolio of leading global brands and bolsters its innovation capabilities and R&D pipeline.
Jeffrey N. Simmons, president and chief executive officer of Elanco, said: "Combining Elanco’s strong relationship with veterinarians and Bayer’s leadership in retail and e-commerce will ultimately benefit all our customers. We look forward to joining our complementary portfolios and capabilities to build a fully focused animal health company, providing a sustained flow of innovation for farmers, veterinarians and pet owners."
1,219 farmers took part in the survey: 44% beef and 56% dairy. For the first time, the survey was also tailored for the regions. 488 responses came from famers in England, 380 from Scotland, 164 from Wales and 237 from Northern Ireland.
Boehringer Ingelheim’s Matt Yarnall, who led the project, said: "Headline findings are that farmers have regrets about holding onto persistently infected animals (PIs) which, at the end of the day, no-one should be doing.
"The financial benefit of being free of BVD was estimated as being over £90 per cow per year and when asked what impact BVD has had on their herd, the majority of producers highlighted poor fertility and high levels of disease in the herd.”
Boehringer says the identification of persistently infected animals (PIs) through tag and testing, supported by improved herd biosecurity and vaccination, could cost as little as £10 per cow per year, representing a significant return on investment for a disease with severe financial impact.
Matt said: "Herd biosecurity is also hugely variable. The most commonly selected response was operating a closed herd but, as most practitioners will know, the definition of a true closed herd and the real-life execution of that can be two very different things."
Highlighting one of the other major challenges for producers in cattle-dense areas, results from Scotland that showed that 51% of farmers with neighbouring cattle are worried about their neighbours' BVD status.
Matt said: "Perhaps the most alarming finding was the lack of awareness of the intricacies of some BVD vaccination courses, especially around when they need to be restarted, in order to achieve the protection needed."
2017 survey data from last year showed that 71% of producers were failing to achieve adequate protection when using a BVD vaccine that requires a booster six months after the primary course.
Boehringer says the results showed this is mostly down to not properly understanding the exact nature of the timings for the two-dose primary course, dates of service and calving and then the booster date.
Matt added: "For any practitioner advising clients, the 2018 finding that a shocking 85% haven’t restarted a vaccination course when the majority should have done, should ideally serve as a clear call to action."
For more information about the findings of the National BVD Survey, email bvdzero.uk@boehringer-ingelheim.com.
The app, which works on tablets and smartphones, allows vets to e-mail audit results directly to clients following an interactive calf health assessment at the farm.
MSD Animal Health’s youngstock marketing manager Robert Simpson said: “Our new app allows both parties to explore, record and score calf health performance across five core areas to identify the strengths and weaknesses of any rearing unit’s environment and processes.
“Working through a series of 10 questions within each core area – designed to tease out where a rearing unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to monitor progress against agreed targets”.
For more information about the app, contact your MSD account manager.
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
US-based Life Technologies has launched a new PCR-based test system which, according to the company, allows large numbers of pigs to be screened more quickly and cost-effectively for a range of common pathogens, such as PRRSV, SIV and PCV2.
The system uses samples of oral fluids which can be obtained by leaving a cotton rope in each pen for pigs to chew on. After 20 minutes or so, the rope can be retrieved and the saliva and gingival crevicular fluid squeezed into a sample bag and represents a pooled sample from the group.
Studies have demonstrated that oral fluid samples collected in this way can form the basis of a quick and cost-effective method for screening a range of common viral pathogens. The samples were tested using a commercially available sample preparation and real-time PCR test system which can isolate and identify viral nucleic acid in a matter of hours.
For PRRS, pooled samples of oral fluids were collected from groups of experimentally infected pigs using the rope technique, along with serum samples from each individual pig on the same days. Both serum samples and oral fluids were processed using the same Applied Biosystems preparation system and real- time PCR test, both of which were supplied by Life Technologies. The results showed that PRRSV nucleic acid was detectable in both serum and oral fluid samples from the day of infection through to 40 days after infection.
For PCV2, 24 pigs that were free of PRRSV and SIV were divided into 4 pens in separate rooms, and challenged with two different virus strains (PCV2a and PVC2b) at different times. One pen acted as a (non-challenged) control. Oral fluids were collected regularly up to 140 days after initial challenge and tested using real-time PCR. High titres of PCV2 were detected from day 12 to day 28 post infection and virus was detectable throughout the entire testing period (days 2 to 98).
For SIV, a total of 180 spiked oral fluid samples were tested using real-time PCR, and subtyping reagents were also used to identify haemagglutinin and neuraminidase subtypes. The results showed that SIV nucleic acid was detectable in oral fluid samples spiked with high, medium and low copy numbers of SIV, and all positive samples could be successfully sub-typed.
Christina Boss, European Professional Service Veterinarian for Life Technologies said: "Collecting samples in this way is far less invasive for the pigs and so avoids unnecessary stress. And because all of the pigs will chew on the rope, it provides a very broad sample from the group, which is the key to assessing overall herd health. In addition, if the pooled sample provides a positive result, then the animals in that pen can be tested individually to identify those that are infected.
"These results show that the simplicity of oral fluid sampling, combined with the speed and sensitivity of a PCR-based system, provides a practical and cost- effective way of monitoring large numbers of pigs for common virus pathogens.
"The use of a semi-automated, PCR-based diagnostic system means that nucleic acid purification can be achieved in just 25 minutes and results from the real-time PCR available in 90 minutes. The molecular test is very specific and reliable, so the veterinarian can initiate individual testing as quickly as possible and make confident recommendations to the producer."
According to Life Technologies, screening for PRRS using samples of oral fluids has been gaining popularity over recent years because large numbers of pigs can be tested without increased cost or labour. The new research is due to be presented as a poster at the ESPHM meeting in Bruges in April.
The role was created last November when the Animal & Plant Health Agency (APHA) started allowing para-professional staff to support vets in carrying out TB testing in England.
UK Farmcare says there are now 49 fully authorised ATTs in England with another 21 TB testing under veterinary supervision and three undergoing the theory part of the training.
To become an ATT, applicants must be at least 18 years old, hold a valid UK driving licence and passport, possess a clean criminal record and then be approved by the APHA. Applicants also need at least three graded GCSEs or equivalent in English, Maths and a science or food production subject and at least six months cattle handling experience.
https://ukfarmcare.com/an-introduction-to-the-att-role.
Bimeda UK has announced that Endofluke 100mg Oral Suspension has been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml) kills all three stages of liver fluke.
Bimeda UK Sales Manager, Andrew Lane said: "This is great news for the UK's dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK's dairy farmers."
Endofluke is a POM-VPS product.
For more information, visit www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on alane@bimeda.com or on 07917 208524.
CEVA Animal Health has announced that its live enzootic abortion vaccine, CEVAC® Chlamydophila, now has an added benefit. It can be used simultaneously with the only available toxoplasmosis vaccine. According to CEVA, infectious abortion, particularly enzootic abortion (Chlamydiosis), has been known to wipe out up to 50% of lambs. Strategic use of CEVAC® Chlamydophila, a live enzootic abortion vaccine, can not only prevent abortion but can also control excretion and the threat of infection.
The company says: "CEVAC® Chlamydophila makes practical and economic sense. A vaccination every four years will help your clients’ flocks remain chlamydiosis-free and the cost of treatment should work out at well under 75p per sheep per year. This is a tiny investment for your clients, to prevent the financial loss of an abortion. The fact that the product can now be used on the same day as the toxoplasmosis vaccine means that is now one of the most convenient and affordable methods currently available."
Ideally routine preventative measures should be taken prior to mating and when new sheep are introduced to the flock, to ensure abortion and infection rates always remain as low as possible.
All animals should be vaccinated in the first year, with replacements being vaccinated from six months of age, at least four weeks prior to tupping.
CEVAC® Chlamydophila is quick and easy to administer, using the special, multi-dose injector gun. One bottle of vaccine contains enough for 20 doses.
For further product information contact your local CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG or visit the website at http://www.ceva.uk.com/
The new Flock Health Checklist is designed to helps practitioners assess performance across the three crucial time periods and two key management processes which have an impact on the success of sheep enterprises.
Dr Kat Baxter-Smith, veterinary adviser with MSD Animal Health said: “We have developed this new performance checklist drawing on specialist sheep vet working experiences, clinical research studies, economic data and industry recommendations.
"For example, the pre-breeding period is a great time to make sure ewes and rams are as fit and healthy as possible.
"Good practice and preparation in this area will go a long way to minimising stress and problems during a busy lambing period.”
Late pregnancy and lambing period is also a vital time – and is the busiest few weeks on any sheep farm.
Kat added: “Having pre-agreed protocols for this important period in the sheep farming calendar – and keeping a record of issues that arise – will go a long way to making sure subsequent lambing seasons go as smoothly as possible.”
Growth, weaning and sale is the third crucial time period and the Flock Health Checklist incorporates an additional series of audit-based questions designed to pinpoint system strengths and weaknesses.
The Flock Health Checklist also enables vets to ask a series of questions covering two key management processes: disease management and biosecurity; and how flock performance is currently monitored.
Kat said: “Working through a series of 10 questions within each of the three crucial time periods and two key management processes – designed to tease out where a sheep unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to montor performance against agreed targets.
“Similar types of checklist have been available to dairy youngstock rearing units and beef suckler herds for a couple of years now, with several vets reporting that these tools have proved integral to their productivity improvement work with farmer clients.
"Use of this checklist-based approach is also helping better implementation of preventative health practices such as vaccination. We hope this latest tool will help the GB sheep industry similarly.”
For further information, contact your local MSD Animal Health account manager.
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
Avishield IB G1-13 is indicated for active immunisation of chicks to reduce the adverse effect on cilia caused by infectious bronchitis.
The vaccine is one of two targeting the IBV 793B serotype and, with the addition of this new claim, Avishield can now be administrated on broiler, broiler breeder and laying hen farms.
Avishield IB GI-13 is a lyophilisate for oculonasal suspension/use in drinking water which contains live avian infectious bronchitis virus variant strain V-173/11: 102.7-104.6 EID50.
It has an onset of immunity 10 days after vaccination and a duration of immunity of 56 days.
Johnny Wells West, poultry key account manager at Dechra Veterinary Products, said: “The new licence extension for Avishield IB G1-13 allows greater flexibility for poultry producers to protect their flocks against infectious bronchitis on broiler, broiler breeder and laying hen farms and it is welcome news for both Dechra and the poultry industry.”
For more information contact Johnny Wells West on 07584 175758 or visit http://www.dechra.co.uk/Avishield IB G1-13
Three new learning aids launched by BVA:
Practical Animal Handling - Online Tutorial The BVA AWF have launched an online tutorial on practical animal handling which has been prepared in conjunction with Newcastle University. The tutorial is primarily aimed at veterinary students and nurses. It features videos of expert veterinary staff demonstrating the correct procedures for handling small animals for clinical examination and medication and its aim is to show that the primary consideration should be for the welfare of the animal. To access the online tutorial visit http://www.bva-awf.org.uk/resources/tutorials/.
Disbudding of Kid Goats The Goat Veterinary Society (GVS) has produced a DVD designed to help veterinary surgeons to disbud goats. Produced in association with the BVA Animal Welfare Foundation the DVD is in memory of the late Mike Teale MRCVS, following a donation from his family. The DVD discusses the potential problems associated with disbudding kid goats and provides guidance on how to avoid them. It shows the best technique for disbudding from start to finish and discusses anatomical considerations, methods of anaesthesia and analgesia and disbudding, with particular attention drawn to the regulatory aspects as they currently apply in the UK. For further information on the GVS DVD, including obtaining a copy, at a cost of £10, please visit http://www.bva-awf.org.uk/headlines/news/Disbudding_of_kid_goats_DVD__2_.pdf.
Bat Care Guidelines - a Guide to Bat Care for RehabilitatorsThe Bat Conservation Trust (BCT) has produced Bat Care Guidelines, in association with the BVA AWF, RSPCA and RCVS Trust, aimed at veterinary professionals, wildlife hospitals and new rehabilitators. The document is split into basic sections including 'health and safety', 'rescue and collection' and 'ailments and treatments' which aim to provide minimum guidelines for bat care. The new initiative is part of an ongoing partnership focusing on the rehabilitation of wild bats in the UK. Visit http://www.bva-awf.org.uk/grants/projects/BCT_workshop_article_08.pdf for further information
Zoetis has announced that a batch of the bluetongue vaccines, Zulvac® 8 Bovis and Zulvac® 8 Ovis, is expected to become available to veterinary practices in mid-July, in time to manage the risk of an outbreak predicted by Defra to reach mainland UK by the late summer.
The company says the quantity of vaccine will not be unlimited and that it will strive to achieve as widespread availability as possible.
The two vaccines (Bovis for cattle and Ovis for sheep) are licensed to “prevent viraemia” caused by bluetongue virus serotype 8 (BTV-8). Prevention of viraemia, the presence of bluetongue virus in the blood, ensures no onward spread of infection via the blood sucking Culicoides midge.
The vaccines can be used in cattle from three months of age, or six weeks in sheep, requiring two doses three weeks apart in either species. Each dose is 2ml administered intramuscularly in cattle or subcutaneously in sheep, and onset of immunity is 25 days after the second dose. The vaccine provides immunity for a full 12 months.
The British Veterinary Association (BVA), British Cattle Veterinary Association (BCVA), Goat Veterinary Society (GVS), and Sheep Veterinary Society (SVS) welcomed the announcement from Zoetis, and another from MSD, but sought clarification about the cost and the amount of vaccine likely to be available in July and thereafter.
BVA President Sean Wensley said: "We welcome the announcement that vaccine will be available in time to meet potential demand. This disease seriously affects animal health and welfare as well as the productivity of livestock, and vaccination is the key control. While it is good news that vaccine will be available, we know that both farmers and vets will have questions about cost and whether there will a limit to the amount of vaccine available in July. It would be helpful to have these questions clarified as soon as possible."
Photo by Fourrure (http://www.boulesdefourrure.fr) [CC BY-SA 2.0], via Wikimedia Commons
With 2024 support payments for farmers in England now at half former levels and significant changes to subsidies for farmers in Scotland and Wales set to come into play next year, Elanco says effective flock health management to maximise efficiency and performance within flocks has become increasingly important.
Elanco's Ruminant Technical Consultant, Matt Colston MRCVS said: “Policymakers recognise the importance of animal health and welfare for better productivity and are putting an increasing onus on vets to deliver improvements, for example via the Animal Health and Welfare Pathway (AHWP).”
“Its crucial vets have the knowledge and confidence to support sheep clients on important flock health issues, with worming programmes high up on this agenda.”
"By developing farm-specific worm control strategies and working closely with clients to better monitor worm burdens, you can help achieve immediate flock performance benefits and manage the longer term risks of anthelmintic resistance on that farm.”
Elanco says that by dosing lambs with its newer Group 4 wormer, Zolvix, at the right time during the mid to late grazing season, farmers can clear out any resistant worms that have survived previous treatments and see an uplift in daily liveweight gain as a result.
Matt added: “We shouldn’t wait for problems to manifest.
"By the time wormer groups have stopped working, or clinical signs of worms are visible, damage is already done; regular monitoring and early intervention is a better option.
“More farmers are Faecal Egg Counting (FEC) but many are unsure how best to go about it.
“A practical demonstration of how to collect samples, and what to collect from which animals, is often the best way to show how easy FEC can be.”
“Farmers can be cautious about change, but by taking small steps and consistently offering sound, practical advice, vets can help farmers adopt more sustainable worm control strategies and improve margins in sheep production.”
Caused by the mite Psoroptes ovis, sheep scab was notifiable in the UK until 1992, after which a voluntary reporting scheme was put in place in England and Wales. Sheep scab was made notifiable again in Scotland in 2010.
The study was suggested by Emily Gascoigne MRCVS of Synergy Vets, who noticed that hers was one of the few practices that appeared to be voluntarily reporting cases in England.
She said: "It’s been observed that that farmers can feel ‘judged’ when sheep scab appears in their flock and the impulse to keep it hidden may hold back efforts to control it.
“The results will help to quantify the problem but we are also tackling the other side of the coin by trying to make sheep scab less of a taboo. The potential for contiguous infection from one farm to the other means that forewarned is forearmed.
"Farmers often blame themselves when their sheep get scab which although it can result from a failure of biosecurity at boundaries or during quarantine, can also be brought in on people, deliveries or equipment. Then there are real worries about whether that will affect the saleability of their stock or their relationship with their farming neighbours. We want to encourage vets and farmers to start the conversation and to start actively testing for sheep scab.”
Around 40 practices within the XLVets community are now taking part in the study. In addition to contributing to the survey, participating practices will also be sharing information with farmers about the importance of testing for sheep scab.
The initiative is being supported by Bimeda UK, which provides an online Sheep Scab Academy to help veterinary surgeons and SQPs stay up to date with best practice for sheep scab control. Bimeda UK’s Professional Services Vet Sharon Cooksey, said: "Bimeda has worked for many years to raise awareness and promote best practice in managing this awful disease, including supporting the launch and ongoing operation of the Biobest ELISA test, so this is an initiative we are happy to support.”
The survey has been running since the start of October and will continue for the next five months, with results expected around March 2021.
The RCVS and the Veterinary Medicines Directorate (VMD) will be holding a free Masterclass offering practical guidance on the requirements of the Veterinary Practice Premises Register, on Saturday 4 April, at BSAVA Congress.
If you are concerned about medicines inspections and would like further information about complying, this is your chance to find out what you need to do.
By 1 April, all practice premises from which medicines are supplied should be registered with the RCVS. All such premises are then subject to inspection - by either Practice Standards Scheme inspectors, if accredited under the Scheme, or VMD inspectors. Will you be ready if an inspector calls?
Suitable for veterinary surgeons, veterinary nurses and practice managers, the interactive session will be held from 10am - 12noon, with presentations from VMD and the Chief Inspector of the Practice Standards Scheme, followed by group discussion and plenty of time for questions and answers.
Attendance at the Masterclass, which will be held in Hall 6 of the ICC in Birmingham, is free to BSAVA passholders.
For your free ticket, contact Fiona Harcourt on 020 7202 0773, f.harcourt@rcvs.org.uk, or during Congress visit the RCVS Stand, number 918, opposite the catering stand in the Exhibition hall.
However, the report also indicates an opportunity for further uptake of teat sealant use as part of selective dry cow therapy.
The report is based on data collected from 940 dairy farmers and 156 vet practices.
Report author Christina Ford said: “The overall message from the report is exceedingly positive.
"79% of herds met the Ruma 2020 target by March 2021, and the decline in use of critically important antimicrobials was outstanding, a drop from 1.1 mg/kg PCU in 2018 to 0.02 mg/kg PCU in 2021.”
There was a large variation between individual herd results, which ranged from 0.28 to 87.51mg/kg PCU in 2021.
Christina said: “We found that it’s not always the same herds in the highest 25% antimicrobial usage year-on-year, nor is it necessarily the same farms consistently using the lowest quantities.
“There’s also no correlation at all when looking at different herd characteristics such as yield, herd size, breed.
"This demonstrates that it’s possible to make strides in reducing antimicrobials use in any farming system."
Senior clinical director at Kingshay, Tim Potter MRCVS says the report shows an opportunity for increased uptake of teat sealants to protect cows from infection without antibiotics.
“The teat sealant usage in 2021 was at 0.39 courses/cow, which was below the Ruma target of 0.7 courses per cow.
“Last year, 37% of herds were not using teat sealants at all, so there’s definitely room for improvement.
"Vets, farmers and wider industry need to work together to address the challenges around teat sealant use.
“Appropriate training around use of teat sealants is essential, as improper use and poor hygiene protocols can result in bacteria being trapped inside the udder, having the opposite effect on cow health and productivity.”
Tim says that vets are seeing increased demand from farmers for training in this area.
“As a result, VetPartners has invested in the training of our vets, and specific training aids to enable us to do this effectively, to ensure we’re able to support our farmers as best we can.”
The first annual Dairy Antimicrobial Focus Report can be downloaded from: https://www.kingshay.com/dairy-costings/dairy-antimicrobial-focus-report/
As Ceva points out, the change gives veterinary surgeons an opportunity to get more involved in parasite control plans and help farmers develop a sustainable parasite control strategy on their farm.
Eprecis injectable contains eprinomectin, the only molecule with zero-milk withdrawal currently available for cattle on the U.K. market.
Ceva highlights that because Eprecis is an injection, there is no risk of product transfer between in-contact animals caused by licking1,2,3 a natural behaviour of cattle, potentially resulting in sub-therapeutic levels of product being absorbed. There is also no risk of reduction in efficacy if dirt or manure is present on the back of the animal4.
The company says injectable formulation results in less active ingredient per animal treated compared to eprinomectin pour-ons; for example using Eprecis injection, a 500kg animal receives 100mg eprinomectin, while a pour-on delivers 250mg per application.
To support the new POM-V classification, Ceva has launched a vet support pack to help veterinary professionals when talking to their farming clients about Eprecis, worming strategies and their parasite control plans. The pack contains a farmer targeted brochure, farmer Q&A and a practical guide with suggestions of when Eprecis can be used. It also includes an infograph for social media posts, a technical booklet and a vet Q&A to help answer the most common questions they may be asked. A series of social media posts are available for vet practices encouraging their clients to discuss worming with their vet.
Kythé Mackenzie BVSc MRCVS, ruminant veterinary adviser at Ceva Animal Health, said: “Ruminants can be parasitised by a range of nematodes, trematodes and external parasites, all of which can have an impact on health and production. A recent publication considered that helminth infections (GIN, lungworm and liver fluke) cost the UK dairy industry close to £145M per year5. Interestingly, the majority of these costs were attributed to lost production (£131M) rather than treatment costs (£14M).
“There is now documented resistance to eprinomectin in small ruminants6 (Haemonchus contortus in goats) and whilst not yet documented in cattle, action needs to be taken to try and delay/minimise this emergence. This requires the use of more sustainable parasite control plans to assist in managing refugia and allowing animals adequate exposure to the parasites to develop natural immunity. Parasite control plans should maximise health, welfare and production whilst minimising the unnecessary use of anthelmintics.”
In the short-term, orders of Eprecis injectable from veterinary wholesalers will be fulfilled by the current POM-VPS product that is in the supply chain before switching to the new packaging later in the season.
For further information contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.